Altium Capital Management LLC lifted its position in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 93.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 685,000 shares of the company's stock after purchasing an additional 330,000 shares during the quarter. Evolus accounts for 2.1% of Altium Capital Management LLC's portfolio, making the stock its 16th largest position. Altium Capital Management LLC owned approximately 1.08% of Evolus worth $7,562,000 at the end of the most recent reporting period.
Several other hedge funds have also added to or reduced their stakes in EOLS. Barclays PLC lifted its holdings in shares of Evolus by 268.0% in the third quarter. Barclays PLC now owns 93,662 shares of the company's stock valued at $1,518,000 after purchasing an additional 68,213 shares in the last quarter. Principal Financial Group Inc. raised its stake in Evolus by 9.8% in the fourth quarter. Principal Financial Group Inc. now owns 33,370 shares of the company's stock valued at $368,000 after buying an additional 2,989 shares during the period. Jane Street Group LLC raised its stake in Evolus by 47.0% in the 3rd quarter. Jane Street Group LLC now owns 91,899 shares of the company's stock valued at $1,489,000 after acquiring an additional 29,396 shares during the period. Lord Abbett & CO. LLC raised its position in shares of Evolus by 23.4% in the third quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company's stock valued at $16,126,000 after purchasing an additional 188,685 shares during the period. Finally, JPMorgan Chase & Co. lifted its position in Evolus by 63.5% during the third quarter. JPMorgan Chase & Co. now owns 169,926 shares of the company's stock worth $2,753,000 after acquiring an additional 65,972 shares during the last quarter. Institutional investors and hedge funds own 90.69% of the company's stock.
Insider Activity
In related news, insider David Moatazedi sold 6,251 shares of Evolus stock in a transaction on Thursday, March 27th. The shares were sold at an average price of $12.40, for a total value of $77,512.40. Following the completion of the sale, the insider now owns 508,619 shares of the company's stock, valued at approximately $6,306,875.60. This trade represents a 1.21 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Rui Avelar sold 27,904 shares of Evolus stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $370,007.04. Following the transaction, the insider now owns 362,467 shares of the company's stock, valued at $4,806,312.42. This represents a 7.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 60,575 shares of company stock valued at $794,369. 6.10% of the stock is currently owned by insiders.
Evolus Trading Up 6.0 %
Shares of NASDAQ EOLS traded up $0.63 during trading on Wednesday, reaching $11.09. The company had a trading volume of 450,160 shares, compared to its average volume of 661,320. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. Evolus, Inc. has a 12 month low of $8.67 and a 12 month high of $17.82. The company's fifty day moving average price is $12.45 and its 200-day moving average price is $13.03. The stock has a market cap of $705.18 million, a P/E ratio of -12.19 and a beta of 0.97.
Analysts Set New Price Targets
EOLS has been the topic of several recent research reports. BTIG Research initiated coverage on Evolus in a research report on Thursday, April 17th. They set a "buy" rating and a $21.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Needham & Company LLC reissued a "buy" rating and issued a $22.00 target price on shares of Evolus in a report on Wednesday, April 9th. Finally, Barclays boosted their price objective on Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research report on Wednesday, March 5th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average price target of $23.75.
View Our Latest Stock Report on EOLS
About Evolus
(
Free Report)
Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Further Reading
Before you consider Evolus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolus wasn't on the list.
While Evolus currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
